B-hPD-1/PD-L1 Mice

Basic Information

Strain Name
C57BL/6-Pdcd1tm1(PDCD1) Cd274tm1(CD274)/Bcgen
Stock Number
120522
Common Name
B-hPD-1/hPD-L1 Mice
Source/Investigator
Bcgen (Beijing Biocytogen Co., Ltd)
Related Genes
PD-1(Programmed death-1); PD-L1 (Programmed cell death ligand-1,also known as B7-H1, CD274)
Species
C57BL/6
Appearance
Black
Genotypes
Homozygous

Targeting Strategy

Details

Phenotype

mRNA Expression Analysis

B-hPD-1/PD-L1 Mice

RT-PCR analysis of the B-hPD-1/hPD-L1 humanized mice. The splenocytes of the B-hPD-1/hPD-L1 homozygous mice showed expression of human PD-1 and PD-L1 mRNA but not mouse PD-1 and PD-L1 mRNA.

Protein Expression Analysis

 

Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/hPD-L1 mice were analyzed by flow cytometry. Mouse PD-1+ and PD-L1+ T cells were detectable in the WT C57BL/6 mice, while human PD-1 and PD-L1+ T cells were detectable in the homozygous B-hPD-1/hPD-L1 mice.

Application

Human PD-L1 (Tecentriq) mAb Efficacy Evaluation (MC38-hPD-L1 Cell Line)

B-hPD-1/PD-L1 Mice

Murine colon cancer MC38-hPD-L1 cells were subcutaneously implanted into homozygous B-hPD-1/hPD-L1 mice. Mice were grouped when the tumor size was approximately 150±50 mm3 (n=5). High dose of human PD-L1 antibody Tecentriq significantly inhibited tumor growth, confirming that the B-hPD-1/hPD-L1 mouse model is a powerful tool for in vivo PD-L1 antibody pharmacological efficacy study. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

Combination Therapy of PD-1 (Keytruda) mAb and PD-L1 (Tecentriq) mAb

B-hPD-1-PD-L1-Mice-combination-therapy

Murine colon cancer MC38-hPD-L1 cells were subcutaneously implanted into homozygous B-hPD-1/hPD-L1 mice. Mice were grouped when the tumor size was approximately 150±50 mm3 (n=6).  Anti-hPD-1 antibody Keytruda, anti-hPD-L1 antibody Tecentriq and Combination of anti-hPD-1 antibody Keytruda and anti-hPD-L1 antibody Tecentriq all show significant inhibitory effects. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

References

  1. Journal of Biomedical Science (2017) 24:26
  2. PLoS ONE 12(4): e0176822. Doi: 10.1371/journal.pone.0176822
  3. NATURE COMMUNICATIONS 7:13354 doi: 10.1038/ncomms13354
Back to top